



Biogen Appoints Adam Feire as Head of Business Development and External Innovation

January 9, 2025

Cambridge, Mass. – January 9, 2025 – [Biogen](#) Inc. (Nasdaq: BIIB) – today announced the appointment of Adam Feire, Ph.D., as Head of Business Development and External Innovation. Mr. Feire reports to Adam Keeney, Ph.D., Executive Vice President and Head of Corporate Development. In this role, Mr. Feire leads the search and evaluation of external opportunities and is responsible for business development transactions including mergers and acquisitions.

“Adam Feire’s extensive business development experience, combined with his track record of building strategic alliances, will help advance Biogen’s goals to achieve sustainable growth,” said Mr. Keeney. “As we look to invest in a diversified pipeline through business development, Adam’s expertise will be instrumental in identifying, evaluating and securing meaningful partnerships to further strengthen the Biogen portfolio.”

Adam Feire brings nearly two decades of pharmaceutical industry experience to Biogen, most recently as the Global Head of Search & Evaluation within Novartis Corporate & Business Development. Adam has led global teams focused on the identification and evaluation of partnering opportunities, ranging from discovery to commercial stage assets. Over the course of his career, Mr. Feire has led drug discovery project teams to bring candidates into the clinic, established technology licensing deals and collaborative partnerships, and directed early and late-stage search and evaluation efforts.

Mr. Feire holds a B.S. degree in Biology from James Madison University and a Ph.D. in Cellular and Molecular Biology from the University of Wisconsin, Madison.

About Biogen

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - [Facebook](#), [LinkedIn](#), [X](#), [YouTube](#).

Biogen Safe Harbor

This news release contains forward-looking statements, including regarding the potential of Biogen’s commercial business and pipeline programs; the anticipated benefits and potential of investments, Biogen’s future strategic and financial results. These statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen’s drug candidates; actual timing and content of submissions to and decisions made by the regulatory authorities regarding our products or product candidates; uncertainty of success in the development and potential commercialization of the medicine; failure to protect and enforce Biogen’s data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks, results of operations and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen’s expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements.

###

MEDIA CONTACT:

Biogen
Jack Cox
+ 1 781 464 3260
public.affairs@biogen.com

INVESTOR CONTACT:

Biogen
Tim Power
+1 781 464 2442
IR@biogen.com